HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Pain Management · Anesthesia Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Pain Management · Anesthesia Therapeutic Area Assessment

196 signals · 14 insights · 863 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 65%

Evidence

1073 items

Sources

4

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Pain Management · Anesthesia integrates 196 signals, 14 executive insights, and 863 regulatory precedents from the Humanexa intelligence graph. 3 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 17, 2026

    B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues

    Braun Medical is recalling convenience kits that contain Bupivacaine Hydrochloride in Dextrose Injection due to safety concerns.

    View detail
  2. signalJun 29, 2026

    FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

    The FDA has approved the Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride submitted by Lannett Co Inc.

    View detail
  3. signalJun 25, 2026

    FDA Approval for Oxycodone Hydrochloride by Novel Labs

    The FDA has granted approval for ANDA204021, a supplemental application for Oxycodone Hydrochloride by Novel Labs.

    View detail
  4. signalJun 20, 2026

    Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk

    Draeger, Inc. is correcting additional anesthesia workstations due to a manufacturing error that may lead to ventilator failure.

    View detail
  5. regulatoryJul 23, 2026

    Other | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.

    View detail
  6. regulatoryJul 23, 2026

    Rare Disease Drug Approvals

    This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

    View detail
  7. regulatoryJul 23, 2026

    Verified Clinical Benefit | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    View detail
  8. regulatoryJul 23, 2026

    CDER proposes to withdraw approval of TAVNEOS

    Why this matters: sets a approval precedent in the same sub-indication (pain) as Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.

    View detail
  9. insightJul 17, 2026

    B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    The recall of B. Braun's spinal anesthesia kits due to safety concerns poses significant risks to the company's market position and reputation. This situation necessitates a thorough investigation to understand the implications for product safety and regulatory compliance. Regulatory context from FDA (FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

    View detail
  10. insightJul 1, 2026

    Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

    View detail
  11. insightJun 30, 2026

    Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

    View detail
  12. insightJun 28, 2026

    Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    The FDA's approval of Sun Pharma's ANDA for Levorphanol Tartrate signifies a new entry into the pain management market, which could disrupt existing pricing structures and market shares. Competitors must be vigilant in adjusting their strategies to maintain their positions in this evolving landscape. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 14 risk-calibrated assessments for portfolio review. 863 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 8 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Other | Cancer Accelerated Approvals

    66%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.

    Source: FDA

    View evidence

  • Rare Disease Drug Approvals

    66%

    This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

    Source: FDA

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    84%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

    Source: FDA

    View evidence

  • CDER proposes to withdraw approval of TAVNEOS

    84%

    Why this matters: sets a approval precedent in the same sub-indication (pain) as Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    84%

    Why this matters: sets a approval precedent in the same sub-indication (pain) as Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)

    66%

    Application ANDA219647. Sponsor: NOVITIUM PHARMA. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: TRAMADOL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    57%

    The recall of B. Braun's spinal anesthesia kits due to safety concerns poses significant risks to the company's market position and reputation. This situation necessitates a thorough investigation to understand the implications for product safety and regulatory compliance. Regulatory context from FDA (FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    69%

    The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    86%

    The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    91%

    The FDA's approval of Sun Pharma's ANDA for Levorphanol Tartrate signifies a new entry into the pain management market, which could disrupt existing pricing structures and market shares. Competitors must be vigilant in adjusting their strategies to maintain their positions in this evolving landscape. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Increased Competition in Opioid Pain Management Following Recent FDA Approvals

    43%

    The FDA's approval of Lannett's oxycodone hydrochloride presents a significant shift in the competitive landscape of the opioid market. This entry may lead to pricing pressures and market share erosion for existing players, requiring strategic responses to maintain competitive positioning. Regulatory context from FDA (FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 15 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Acertis Pharmaceuticals Gains Regulatory Momentum with Levorphanol Tartrate Application

    89%

    The FDA's acceptance of the supplemental application for Levorphanol Tartrate by Acertis Pharmaceuticals is significant as it positions Acertis to strengthen its foothold in the competitive opioid pain management market. This development necessitates close monitoring of market dynamics and potential responses from other manufacturers. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues

    Safety Signal

  • FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc

    Regulatory Approval

  • FDA Approval for Oxycodone Hydrochloride by Novel Labs

    Regulatory Approval

  • Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk

    Safety Signal

  • FDA Approves Supplement for Buprenorphine Hydrochloride by Rubicon Research

    Regulatory Approval

  • Zydus Pharms receives AP status for Dexmedetomidine Hydrochloride ANDA206798

    Regulatory Approval

  • FDA Grants Approval for Novitium's Tramadol Hydrochloride

    Regulatory Approval

  • Trial Comparing Liposomal Bupivacaine and Dexamethasone for Postoperative Pain Control

    Trial Update

Insights

  • B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    Anesthesia · Injectable

  • Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    Anesthesia · Local Anesthetic

  • Omega Pharma Faces Market Risks from Napralief Recall Amid Competitive Pressures

    Pain Management · OTC

  • Sun Pharma's Levorphanol Tartrate Approval Disrupts Pain Management Landscape

    Pain Management · Opioid

  • Increased Competition in Opioid Pain Management Following Recent FDA Approvals

    Pain Management · Opioid

  • Acertis Pharmaceuticals Gains Regulatory Momentum with Levorphanol Tartrate Application

    Pain Management · Opioid

  • Regulatory Scrutiny Intensifies Following Aspar Pharmaceuticals' Ibuprofen Recall

    Pain Management · NSAID

  • FDA Approval of Succinylcholine Chloride: New Competitive Dynamics in Neuromuscular Blockers

    Anesthesia · Neuromuscular Blocker

Companies

  • Hikma

    30 signals

  • Teva

    25 signals

  • Aurobindo Pharma

    28 signals

  • Sun Pharma

    24 signals

  • Novitium Pharma

    16 signals

  • Sciegen Pharmaceuticals

    15 signals

  • Strides Pharma

    12 signals

  • Macleods Pharmaceuticals

    10 signals

Assets

  • Hospira
  • Levorphanol Tartrate
  • Levorphanol Tartrate
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.